Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 11/20 | 1.00 |
| ▸ | GLO1 | Q04760 | 8/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 2/20 | 1.00 |
| ▸ | NFKBIA | P25963 | 2/20 | 1.00 |
| ▸ | G6PD | P11413 | 1/20 | 1.00 |
| ▸ | METAP2 | P50579 | 1/20 | 1.00 |
| ▸ | METAP1 | P53582 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | MITF | O75030 | 1/20 | 0.76 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.76 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7746129 | 0.98 | SLC40A1 (0.97) | SLC40A1GLO1TDP1AGTR1NFKBIA | |
| SCHEMBL13485924 | 0.91 | GLO1 (0.84) | SLC40A1GLO1TDP1AGTR1NFKBIA | |
| SCHEMBL13638616 | 0.87 | SLC40A1 (0.76) | SLC40A1GLO1TDP1AGTR1NFKBIA | |
| SCHEMBL3825367 | 0.87 | TDP1 (1.00) | SLC40A1GLO1TDP1AGTR1NFKBIA | |
| SCHEMBL30925462 | 0.87 | SLC40A1 (1.00) | SLC40A1GLO1TDP1AGTR1NFKBIA | |
| SCHEMBL11973652 | 0.87 | SLC40A1 (1.00) | SLC40A1GLO1TDP1AGTR1NFKBIA | |
| SCHEMBL6978005 | 0.87 | GLO1 (1.00) | SLC40A1GLO1TDP1AGTR1NFKBIA | |
| SCHEMBL6981081 | 0.87 | SLC40A1 (1.00) | SLC40A1GLO1TDP1AGTR1NFKBIA | |
| SCHEMBL30925586 | 0.87 | SLC40A1 (1.00) | SLC40A1GLO1TDP1AGTR1NFKBIA | |
| SCHEMBL29799662 | 0.87 | TDP1 (1.00) | SLC40A1GLO1TDP1AGTR1NFKBIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651595-A2 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11691949-B2 | Quinoline sulfonamide compounds and their use as antibacterial agents | OTAGO INNOVATION LIMITED (NZ) | 2023-07-04 | — | — | US | disclosed |
| US-11213701-B2 | Neuroprotective quinoline sulfonamides | DAHL RUSSELL (US) | 2022-01-04 | — | — | US | disclosed |
| US-11213701-B2 | Neuroprotective quinoline sulfonamides | DAHL RUSSELL (US) | 2022-01-04 | — | — | US | disclosed |
| WO-2021146082-A1 | BIHETEROCYCLIC INHIBITORS OF ISPF FOR TREATMENT OF MICROBIAL INFECTIONS | POINT LOMA NAZARENE UNIVERSITY (US) | 2021-07-22 | — | — | WO | disclosed |
| US-20210005827-A1 | N AND P ACTIVE MATERIALS FOR ORGANIC PHOTOELECTRIC CONVERSION LAYERS IN ORGANIC PHOTODIODES | SONY CORPORATION (JP) | 2021-01-07 | — | — | US | disclosed |
| US-10790454-B2 | N and P active materials for organic photoelectric conversion layers in organic photodiodes | SONY CORPORATION (JP) | 2020-09-29 | — | — | US | disclosed |
| US-20200188706-A1 | NEUROPROTECTIVE QUINOLINE SULFONAMIDES | DAHL RUSSELL (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200188706-A1 | NEUROPROTECTIVE QUINOLINE SULFONAMIDES | DAHL RUSSELL (US) | 2020-06-18 | — | — | US | disclosed |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-02-18 | — | — | US | disclosed |
| WO-2008131192-A2 | CRYSTALLINE CHOLESTROL AND PREVENTION OF ATHEROSCLEROSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-10-30 | — | — | WO | disclosed |
| US-7183320-B2 | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | ELI LILLY AND COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| EP-0991624-B1 | PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-11-19 | — | — | EP | disclosed |
| EP-0675358-B1 | Monitoring water treatment agent in-system concentration and regulating dosage | NALCO CHEMICAL CO (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6528187-B1 | Luminescence element comprising pair of electrodes having formed therebetween plurality of organic compound thin film layers comprising electron-transporting layer which comprises specified compound | FUJI PHOTO FILM CO., LTD. (JP) | 2003-03-04 | — | — | US | disclosed |
| EP-0991624-A1 | PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT | Boehringer Ingelheim Pharma KG (DE) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999000371-A1 | PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-01-07 | — | — | WO | disclosed |
| EP-0675358-A1 | Monitoring water treatment agent in-system concentration and regulating dosage | NALCO CHEMICAL COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10790454-B2 | N and P active materials for organic photoelectric conversion layers in organic photodiodes | L1CAM, PNN, JUP | SLC40A1 3003/4885GLO1 2556/4885TDP1 601/4885 |
| US-20200188706-A1 | NEUROPROTECTIVE QUINOLINE SULFONAMIDES | SUMO3, SUMO2, PSEN1 | SLC40A1 4609/4885GLO1 2894/4885TDP1 522/4885 |
| US-11213701-B2 | Neuroprotective quinoline sulfonamides | SUMO3, SUMO2, PSEN1 | SLC40A1 4609/4885GLO1 2894/4885TDP1 522/4885 |
| US-11691949-B2 | Quinoline sulfonamide compounds and their use as antibacterial agents | NQO2, SDHA, SIRT5 | SLC40A1 4081/4885GLO1 369/4885TDP1 4605/4885 |
| US-20210005827-A1 | N AND P ACTIVE MATERIALS FOR ORGANIC PHOTOELECTRIC CONVERSION LAYERS IN ORGANIC PHOTODIODES | L1CAM, PNN, JUP | SLC40A1 3003/4885GLO1 2556/4885TDP1 601/4885 |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | HELZ, MMEL1, GAA | SLC40A1 408/4885GLO1 2965/4885TDP1 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.